Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > RBC STATES RISKS ON THEIR LAST REPORT
View:
Post by Health123 on Oct 16, 2016 11:08am

RBC STATES RISKS ON THEIR LAST REPORT

Risks

The company faces a number of risks related to integration/ execution of acquisitions, the inability to identify new products, Donnatal exposure as a DESI product, clinical trial failures, unexpected new generic drugs, reliance on third parties for various operational items such as manufacturing, price increase pushback, a significant debt load, and risks associated with managing a larger suite of products. However, the AMCo and Covis deals reduce the overall exposure to Donnatal. Given Concordia's international exposure to the UK and EU, the recent Brexit vote and the subsequent effects on the GBP are a risk to Concordia. The recently tabled NHS bill in the UK could further limit potential future price increases and could also potentially see the NHS impose lower prices for unbranded drugs in the UK. There remains a lack of clarity surrounding the NHS's intentions when it comes to potentially lowering drug prices. We also believe that there is significant potential that the UK's Flynn/Pfizer CMA investigation ruling could be negative and the companies could be fined etc... - we believe this would place an overhang on Concordia. 

Comment by ConfidentDD on Oct 16, 2016 11:20am
Indeed. And after that report, the Founder called the Chair and implored him to find the CEO, sit him down and give him the 'WTF' rundown. The CEO replied "amongst us three, Scotch would be fine".
Comment by CounterAttack on Oct 16, 2016 11:29am
This post has been removed in accordance with Community Policy
Comment by LaticelnExile on Oct 16, 2016 11:57am
This post has been removed in accordance with Community Policy
Comment by ConfidentDD on Oct 16, 2016 12:07pm
To Latic's point, its already underway. https://www.telegraph.co.uk/news/2016/06/04/watchdog-to-investigate-extortionate-drugs-pricing-claims/ quote=LaticelnExile]HA!  The Biggest Risk in the UK is THIS....    The CMA is the UK’s primary competition and consumer authority. It is an independent non-ministerial government department with responsibility for carrying ...more  
Comment by LaticelnExile on Oct 16, 2016 12:34pm
This post has been removed in accordance with Community Policy
Comment by ConfidentDD on Oct 16, 2016 12:50pm
True. So the 60 or so new product launches (read Big Mac, Double Big Mac, Mini Big Mac, Big Mac with fries (S,M,L), Big Mac flavoured coffee........in a tube, by IV drip) are doubtless flakey fakes. NHS crats don't even get to Whitehall these days, without good PR in toe. Wonder what geo politics lies ahead for CXR in the other 99 countries. [/quote]
Comment by LaticelnExile on Oct 16, 2016 1:04pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities